Summit Therapeutics (SMMT) Non Operating Income (2020 - 2026)
Summit Therapeutics' (SMMT) quarterly Non Operating Income came in at $4.8 million in Q2 2026, up 75.74% YoY from $2.7 million in Q2 2025, and down 17.14% on a QoQ basis from $5.8 million in Q1 2026.
Summit Therapeutics (SMMT) Non Operating Income (2020 - 2026) Analysis & Trends
Summit Therapeutics (SMMT) has 7 years of Non Operating Income data on file, last reported at $4.8 million in Q2 2026.
- Quarterly Non Operating Income rose 75.74% year-over-year to $4.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $18.8 million (up 19.73% YoY) and the FY2025 annual result came in at $14.8 million, up 10.99% from the prior year.
- Non Operating Income retreated to $4.8 million in Q2 2026, from $5.8 million in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $16.1 million in Q4 2023 to a low of -$5.2 million in Q1 2023.
- A 5-year average of $2.6 million and a median of $2.6 million in 2025 frame the typical range for Non Operating Income.
- Annual changes were most pronounced in 2022 — Non Operating Income sank 3833.63% — and 2024, when it soared 689.95%.
- Tracing SMMT's Non Operating Income over 5 years: stood at $5.5 million in 2022, then surged by 194.35% to $16.1 million in 2023, then plunged by 72.55% to $4.4 million in 2024, then jumped by 30.16% to $5.8 million in 2025, then retreated by 16.63% to $4.8 million in 2026.
- The last three Non Operating Income figures came in at $4.8 million (Q2 2026), $5.8 million (Q1 2026), and $5.8 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Summit Therapeutics | 10.59 Bn | 9.90 Bn | - | 4.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.80 Mn |
| Mar 31, 2026 | 5.79 Mn |
| Dec 31, 2025 | 5.75 Mn |
| Sep 30, 2025 | 2.42 Mn |
| Jun 30, 2025 | 2.73 Mn |
| Mar 31, 2025 | 3.94 Mn |
| Dec 31, 2024 | 4.42 Mn |
| Sep 30, 2024 | 4.58 Mn |
| Jun 30, 2024 | 2.33 Mn |
| Mar 31, 2024 | 2.04 Mn |
| Dec 31, 2023 | 16.10 Mn |
| Sep 30, 2023 | -776,000.00 |
| Jun 30, 2023 | 1.08 Mn |
| Mar 31, 2023 | -5.22 Mn |
| Dec 31, 2022 | 5.47 Mn |
| Sep 30, 2022 | -4.45 Mn |
| Jun 30, 2022 | -4.08 Mn |
| Mar 31, 2022 | 761,000.00 |
| Dec 31, 2021 | -1.05 Mn |
| Sep 30, 2021 | -113,000.00 |